Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
450.8 USD | +0.73% | +2.31% | +10.79% |
May. 22 | Vertex Pharmaceuticals Insider Sold Shares Worth $6,795,294, According to a Recent SEC Filing | MT |
May. 21 | ADDvise Group’s Axelerist Bags $1.4 Million Order for Medical, Lab Equipment | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 29.62 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+10.79% | 116B | B+ | ||
+11.65% | 106B | B+ | ||
-6.20% | 23.89B | B+ | ||
-3.52% | 21.58B | B | ||
-10.00% | 18.96B | A- | ||
-13.41% | 16.33B | B | ||
-40.50% | 16.96B | A- | ||
+6.64% | 14.14B | C+ | ||
+31.84% | 12.02B | C+ | ||
-34.35% | 7.2B | D |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- VRTX Stock
- Ratings Vertex Pharmaceuticals Incorporated